{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:35:39Z","timestamp":1787654139973,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12325-021-01853-0","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T17:02:47Z","timestamp":1628442167000},"page":"4872-4884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults\/Adolescents with Severe Haemophilia\u00a0A"],"prefix":"10.1007","volume":"38","author":[{"given":"Santiago","family":"Bonanad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kurnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"Andreozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Vandewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,8]]},"reference":[{"issue":"6","key":"1853_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5312\/wjo.v7.i6.370:10.5312\/wjo.v7.i6.370","volume":"7","author":"EC Rodriguez-Merchan","year":"2016","unstructured":"Rodriguez-Merchan EC, Valentino LA. Orthopedic disorders of the knee in hemophilia: a current concept review. World J Orthop. 2016;7(6):370\u20135. https:\/\/doi.org\/10.5312\/wjo.v7.i6.370:10.5312\/wjo.v7.i6.370.","journal-title":"World J Orthop"},{"issue":"8","key":"1853_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/MBC.0000000000000571:10.1097\/MBC.0000000000000571","volume":"27","author":"G Auerswald","year":"2016","unstructured":"Auerswald G, Dolan G, Duffy A, et al. Pain and pain management in haemophilia. Blood Coagul Fibrinolysis. 2016;27(8):845\u201354. https:\/\/doi.org\/10.1097\/MBC.0000000000000571:10.1097\/MBC.0000000000000571.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl 6","key":"1853_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"issue":"4","key":"1853_CR4","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1111\/hae.12125","volume":"19","author":"B O'Mahony","year":"2013","unstructured":"O\u2019Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe\u2014a survey of 35 countries. Haemophilia. 2013;19(4):e239-247. https:\/\/doi.org\/10.1111\/hae.12125.","journal-title":"Haemophilia"},{"issue":"4","key":"1853_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2450\/2011.0092-10","volume":"9","author":"A Gringeri","year":"2011","unstructured":"Gringeri A. Factor\u00a0VIII safety: plasma-derived versus recombinant products. Blood Transfus. 2011;9(4):366\u201370. https:\/\/doi.org\/10.2450\/2011.0092-10.","journal-title":"Blood Transfus"},{"key":"1853_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fmed.2019.00261","volume":"6","author":"M Schiavoni","year":"2019","unstructured":"Schiavoni M, Napolitano M, Giuffrida G, et al. Status of recombinant factor\u00a0VIII concentrate treatment for hemophilia\u00a0A in Italy: characteristics and clinical benefits. Front Med (Lausanne). 2019;6:261. https:\/\/doi.org\/10.3389\/fmed.2019.00261.","journal-title":"Front Med (Lausanne)"},{"key":"1853_CR7","unstructured":"European Medicines Agency. Advate (octocog alfa). Authorisation details. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/advate#authorisation-details-section. Accessed May 2021."},{"key":"1853_CR8","unstructured":"Takeda Manufacturing Austria AG. Advate Summary of Product Characteristics 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/advate-epar-product-information_en.pdf. Accessed May 2021."},{"issue":"Suppl 1","key":"1853_CR9","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1111\/jth.12929","volume":"13","author":"A Tiede","year":"2015","unstructured":"Tiede A. Half-life extended factor\u00a0VIII for the treatment of hemophilia\u00a0A. J Thromb Haemost. 2015;13(Suppl 1):S176-179. https:\/\/doi.org\/10.1111\/jth.12929.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1853_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1365-2516.2009.02077.x","volume":"15","author":"E Berntorp","year":"2009","unstructured":"Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia. 2009;15(6):1219\u201327. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02077.x.","journal-title":"Haemophilia"},{"issue":"sup1","key":"1853_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2018.1564032","volume":"12","author":"M Escobar","year":"2019","unstructured":"Escobar M, Santagostino E, Mancuso ME, et al. Switching patients in the age of long-acting recombinant products? Expert Rev Hematol. 2019;12(sup1):1\u201313. https:\/\/doi.org\/10.1080\/17474086.2018.1564032.","journal-title":"Expert Rev Hematol"},{"key":"1853_CR12","unstructured":"Swedish Orphan Biovitrum AB. Elocta Summary of Product Characteristics 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elocta-epar-product-information_en.pdf. Accessed May 2021."},{"key":"1853_CR13","unstructured":"European Medicines Agency. Elocta (efmoroctocog alfa). Authorisation details. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elocta#authorisation-details-section. Accessed May 2021."},{"issue":"3","key":"1853_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor\u00a0VIII Fc fusion protein in severe hemophilia\u00a0A. Blood. 2014;123(3):317\u201325. https:\/\/doi.org\/10.1182\/blood-2013-10-529974.","journal-title":"Blood"},{"issue":"5","key":"1853_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/hae.12985","volume":"22","author":"R Klamroth","year":"2016","unstructured":"Klamroth R, Simpson M, von Depka-Prondzinski M, et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(\u00ae) ) in patients with severe haemophilia\u00a0A. Haemophilia. 2016;22(5):730\u20138. https:\/\/doi.org\/10.1111\/hae.12985.","journal-title":"Haemophilia"},{"issue":"5","key":"1853_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/blood-2016-01-687434","volume":"128","author":"J Mahlangu","year":"2016","unstructured":"Mahlangu J, Kuliczkowski K, Karim FA, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia\u00a0A. Blood. 2016;128(5):630\u20137. https:\/\/doi.org\/10.1182\/blood-2016-01-687434.","journal-title":"Blood"},{"issue":"4","key":"1853_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/jth.13647","volume":"15","author":"O Stasyshyn","year":"2017","unstructured":"Stasyshyn O, Djambas Khayat C, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia\u00a0A: results of a multicenter clinical trial. J Thromb Haemost. 2017;15(4):636\u201344.","journal-title":"J Thromb Haemost"},{"key":"1853_CR18","unstructured":"ClinicalTrials.gov. An open-label safety and efficacy study of recombinant FVIII in patients with severe hemophilia\u00a0A (NCT02172950). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02172950. Accessed May 2021."},{"issue":"1","key":"1853_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.thromres.2014.03.028","volume":"134","author":"S Zollner","year":"2014","unstructured":"Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor\u00a0VIII. Thromb Res. 2014;134(1):125\u201331. https:\/\/doi.org\/10.1016\/j.thromres.2014.03.028.","journal-title":"Thromb Res"},{"key":"1853_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev.me.36.020185.002225","volume":"36","author":"DJ Greenblatt","year":"1985","unstructured":"Greenblatt DJ. Elimination half-life of drugs: value and limitations. Annu Rev Med. 1985;36:421\u20137. https:\/\/doi.org\/10.1146\/annurev.me.36.020185.002225.","journal-title":"Annu Rev Med"},{"issue":"4","key":"1853_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/hae.12375","volume":"20","author":"A Gringeri","year":"2014","unstructured":"Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20(4):459\u201363. https:\/\/doi.org\/10.1111\/hae.12375.","journal-title":"Haemophilia"},{"key":"1853_CR22","unstructured":"CSL Behring. AFSTYLA Summary of Product Characteristics 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/afstyla-epar-product-information_en.pdf. Accessed May 2021."},{"issue":"6","key":"1853_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","volume":"33","author":"KJ Ishak","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537\u201349. https:\/\/doi.org\/10.1007\/s40273-015-0271-1.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1853_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311. https:\/\/doi.org\/10.1177\/0272989X17725740.","journal-title":"Med Decis Making"},{"issue":"3","key":"1853_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","volume":"10","author":"LA Valentino","year":"2012","unstructured":"Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia\u00a0A management. J Thromb Haemost. 2012;10(3):359\u201367. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04611.x.","journal-title":"J Thromb Haemost"},{"key":"1853_CR26","unstructured":"ClinicalTrials.gov. A-LONG: an open-label, multicenter evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor\u00a0VIII Fc fusion protein (rFVIIIFc) in the prevention and treatment of bleeding in previously treated subjects with severe hemophilia\u00a0A. Study results. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01181128. Accessed May 2021."},{"key":"1853_CR27","unstructured":"R Core Team. R: a language and environment for statistical computing [computer program]. 2019. Vienna: R Foundation for Statistical Computing."},{"issue":"5","key":"1853_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2516.2004.00932.x","volume":"10","author":"MD Tarantino","year":"2004","unstructured":"Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia\u00a0A. Haemophilia. 2004;10(5):428\u201337. https:\/\/doi.org\/10.1111\/j.1365-2516.2004.00932.x.","journal-title":"Haemophilia"},{"issue":"9","key":"1853_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/2040620718796429","volume":"9","author":"T Lambert","year":"2018","unstructured":"Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295\u2013308. https:\/\/doi.org\/10.1177\/2040620718796429.","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"1853_CR30","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","volume":"128","author":"SW Pipe","year":"2016","unstructured":"Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia\u00a0A. Blood. 2016;128(16):2007\u201316. https:\/\/doi.org\/10.1182\/blood-2016-04-713289.","journal-title":"Blood"},{"issue":"3","key":"1853_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/hae.13438","volume":"24","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII\u2014a critical review of the evidence. Haemophilia. 2018;24(3):348\u201358.","journal-title":"Haemophilia"},{"key":"1853_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14313","author":"PM Mannucci","year":"2021","unstructured":"Mannucci PM, Cortesi PA, Di Minno MND, Sano M, Mantovani LG, Di Minno G. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia\u00a0A. Haemophilia. 2021;27(4):e422\u201333. https:\/\/doi.org\/10.1111\/hae.14313.","journal-title":"Haemophilia"},{"key":"1853_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/JBM.S104074","volume":"7","author":"J Pocoski","year":"2016","unstructured":"Pocoski J, Li N, Ayyagari R, et al. Matching-adjusted indirect comparisons of efficacy of BAY 81\u20138973 vs two recombinant factor\u00a0VIII for the prophylactic treatment of severe hemophilia\u00a0A. J Blood Med. 2016;7:129\u201337. https:\/\/doi.org\/10.2147\/JBM.S104074.","journal-title":"J Blood Med"},{"key":"1853_CR34","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1016\/j.jval.2018.04.1670","volume":"21","author":"R Ayyagari","year":"2018","unstructured":"Ayyagari R, Deschaseaux C, Vashi P, Kessabi S, Gao W. Matching-adjusted indirect comparisons (MAICs) of efficacy and consumption of BAY 94\u20139027 versus three recombinant factor\u00a0VIII (rFVIII) for prophylaxis of severe hemophilia\u00a0A. Value Health. 2018;21:S246.","journal-title":"Value Health"},{"key":"1853_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/JBM.S206806","volume":"10","author":"K Batt","year":"2019","unstructured":"Batt K, Gao W, Ayyagari R, et al. Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94\u20139027 versus three recombinant factor\u00a0VIII agents for prophylaxis in patients with severe hemophilia\u00a0A. J Blood Med. 2019;10:147\u201359. https:\/\/doi.org\/10.2147\/JBM.S206806.","journal-title":"J Blood Med"},{"issue":"2","key":"1853_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s12325-020-01599-1","volume":"38","author":"Z Hakimi","year":"2021","unstructured":"Hakimi Z, Santagostino E, Postma MJ, Nazir J. Recombinant FVIIIFc versus BAY 94\u20139027 for treatment of patients with haemophilia\u00a0A: comparative efficacy using a matching adjusted indirect comparison. Adv Ther. 2021;38(2):1263\u201374. https:\/\/doi.org\/10.1007\/s12325-020-01599-1.","journal-title":"Adv Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01853-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01853-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01853-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:30:21Z","timestamp":1630438221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01853-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,8]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01853-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,8]]},"assertion":[{"value":"21 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}